Merck Serono S.A.-Geneva*, 9 chemin des Mines, 1202 Geneva, Switzerland.
Expert Rev Med Devices. 2011 Sep;8(5):543-53. doi: 10.1586/erd.11.29. Epub 2011 Jul 6.
Disease-modifying drugs (DMDs) can provide important benefits for patients with multiple sclerosis (MS), but nonadherence to treatment is associated with an increased risk of relapse. All first-line DMDs used in MS require regular injection, but injection-related problems are common barriers to treatment adherence. Autoinjectors that allow automatic injection at the press of a button have increased the ease and convenience of injection, compared with manual injection. A new electronic autoinjector has recently been introduced for the administration of subcutaneous IFN-β-1a. This device is the first electronic autoinjector for use with any MS therapy, and includes several innovative features that may be advantageous to patients. One of these features is an accurate electronic dosing log, which can be viewed by the patient and the healthcare provider. This article discusses this new electronic device in the context of other autoinjectors currently used to self-inject first-line DMDs in MS.
疾病修正药物（DMDs）可为多发性硬化症（MS）患者提供重要益处，但治疗不依从与复发风险增加相关。所有用于 MS 的一线 DMDs 需要定期注射，但与注射相关的问题是治疗依从性的常见障碍。与手动注射相比，可一键自动注射的自动注射器增加了注射的简便性。最近推出了一种新的电子自动注射器，用于皮下注射 IFN-β-1a。该设备是第一个用于任何 MS 治疗的电子自动注射器，包含几个可能对患者有益的创新功能。其中一个功能是准确的电子剂量记录，患者和医疗保健提供者均可查看。本文在当前用于自行注射 MS 一线 DMDs 的其他自动注射器的背景下讨论了这种新的电子设备。
